The IC50 value of crizotinib for TFG-MET fusion is 20.01 nM (Figure 4D), which is similar to that for MET exon14 skipping mutation (22-28.9 nM).17 The median progression-free survival (PFS) was 7.3 months in patients with NSCLC harboring the MET exon 14 skipping mutation and were administered crizotinib as the first-line treatment. This evidence concerns the gene TFG and non-small cell lung carcinoma.